Screener
Halozyme Therapeutics HALO Income Tax
Income Tax at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncomeTaxExpenseBenefit.
The source filing: Halozyme Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001159036-26-000104
| Line item | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| Investment and other income, net | 2,836 | 6,891 | 4,154 | 13,709 |
| Interest expense | (5,588) | (4,394) | (11,096) | (8,919) |
| Income before income tax expense | 284,902 | 204,938 | 465,229 | 348,766 |
| Income tax expense | 54,989 | 39,778 | 85,267 | 65,511 |
| Net income | $229,913 | $165,160 | $379,962 | $283,255 |
| Earnings per share | ||||
| Basic | $1.96 | $1.36 | $3.23 | $2.32 |
| Diluted | $1.90 | $1.33 | $3.11 | $2.26 |
Item 1. Financial Statements
FAQ
- What is Halozyme Therapeutics's income tax?
- Halozyme Therapeutics (HALO) reported income tax of $54.99M in Q2 2026.
- How has Halozyme Therapeutics's income tax changed year-over-year?
- Halozyme Therapeutics's income tax increased by 38.2% year-over-year, from $39.78M to $54.99M.
- What is the long-term trend for Halozyme Therapeutics's income tax?
- Over 4 years (2021 to 2025), Halozyme Therapeutics's income tax has grown at a -0.7% compound annual growth rate (CAGR), from -$154.19M to $149.99M.
- What does income tax mean?
- Total income tax expense (current + deferred) recognized in the income statement, representing the company's total tax obligation on pre-tax income.
Ask your AI about Halozyme Therapeutics's income tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude